Extensive studies have been performed on acute mountain sickness (AMS), but biomarkers predicting AMS are lacking. Presently, the mainstay methods to identify AMS biomarkers include proteomic and genetic methods at high altitudes or in hypoxic simulated chambers. In the present study, we compared plasma cytokine profiles between AMS-susceptible individuals and AMS-resistant individuals at low altitude by cytokine array analysis. In total, 75 differentially expressed cytokines were identified between AMS-susceptible individuals and AMS-resistant individuals, most involved in inflammation. A quantifiable human custom cytokine antibody array was then used to further test results of cytokine array analysis. Compared to AMS-resistant individuals, the level of insulin-like growth factor binding protein 6 (IGFBP-6) was significantly lower in AMS-susceptible individuals (37,318.99 ± 23,493.11 pg/mL and 25,665.38 ± 25,691.29 pg/mL, respectively; P = 0.04). Conversely, the levels of serum amyloid A1 (SAA1), dickkopf WNT signaling pathway inhibitor 4 (Dkk4), and interleukin 17 receptor A (IL-17RA) were significantly higher in AMS-susceptible individuals than in AMS-resistant individuals (SAA1: 4,069.69 ± 2,502.93 pg/mL vs. 2,994.98 ± 2,295.91 pg/mL, P = 0.05; Dkk4: 2,090.00 ± 2,094.89 pg/mL vs. 1,049.88 ± 1,690.93 pg/mL, P = 0.07; IL-17RA: 11.52 ± 8.33 pg/mL vs. 8.67 ± 6.22 pg/mL, P = 0.08). Although further in-depth research is required to examine the possible role of these cytokines in the development of AMS, these four cytokines may be of use in predicting AMS-susceptibility in a low-altitude environment.

中文翻译：

---

血浆细胞因子谱分析可预测对急性高山病的易感性。

已经对急性高山病（AMS）进行了广泛的研究，但是缺乏预测AMS的生物标志物。目前，鉴定AMS生物标志物的主要方法包括在高海拔或缺氧模拟室内的蛋白质组学和遗传学方法。在本研究中，我们通过细胞因子阵列分析比较了低海拔地区AMS易感人群和AMS抗性人群之​​间的血浆细胞因子谱。在AMS易感人群和AMS抗性人群之​​间，总共鉴定出75种差异表达的细胞因子，其中大多数与炎症有关。然后将可量化的人类定制细胞因子抗体阵列用于细胞因子阵列分析的进一步测试结果。与抗AMS的人相比，在AMS易感人群中，胰岛素样生长因子结合蛋白6（IGFBP-6）的水平显着降低（分别为37,318.99±23,493.11 pg / mL和25,665.38±25,691.29 pg / mL； P = 0.04）。相反，在AMS易感人群中，血清淀粉样蛋白A1（SAA1），dickkopf WNT信号通路抑制剂4（Dkk4）和白介素17受体A（IL-17RA）的水平显着高于对AMS耐药的人群（SAA1：4,069.69 ±2,502.93 pg / mL与2,994.98±2,295.91 pg / mL，P = 0.05; Dkk4：2,090.00±2,094.89 pg / mL与1,049.88±1,690.93 pg / mL，P = 0.07; IL-17RA：11.52±8.33 pg / mL与8.67±6.22 pg / mL，P = 0.08）。尽管需要进行更深入的研究以检查这些细胞因子在AMS的发展中可能发挥的作用，